The recommendation is backed by data from the phase 3 LITESPARK-011 trial.
|Videos|September 25, 2020
Gender disparity seen with renal cell carcinoma management
Author(s)Urology Times staff
Meredith R. Metcalf, MD, discusses recent research evaluating management of clinical T1a RCC in men and women.
Advertisement
In this interview, Meredith R. Metcalf, MD, discusses a paper published in Urology titled "Gender Differences in the Clinical Management of Renal Cell Carcinoma," for which she served as a study author. Metcalf is instructor of urology at Johns Hopkins University, Baltimore.
Advertisement
Related to this article
William Huang, MD, discusses histotripsy for renal tumors, the #HOPE4KIDNEY trial, and the technology’s potential to preserve kidney function.
The final analysis confirmed PFS and response benefits in previously treated advanced clear cell renal cell carcinoma, but the OS difference did not cross the prespecified significance boundary.
Advertisement
Advertisement
Trending on Urology Times
1
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
2
FDA grants breakthrough therapy designation to 64Cu-SAR-bisPSMA for recurrent prostate cancer imaging
3
Treatment interruptions in prostate cancer: Balancing PSA kinetics and quality of life
4
Q&A: Where ProACT fits in the male stress urinary incontinence algorithm
5